Market & Alt Data
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-21 | 2026-09-22 | Muken Ross | Director & Chief Executive Officer | Sale | 422 | $8.33 | $4K | 670.2K | View | |
| 2026-09-21 | 2026-09-22 | CARDOZA GEORGE | Chief Financial Officer | Sale | 774 | $8.33 | $6K | 308.3K | View | |
| 2026-09-14 | 2026-09-16 | Menu Philippe | Chief Medical Officer | Sale | 5,000 | $7.88 | $39K | 208.4K | View | |
| 2026-09-14 | 2026-09-16 | Xu Zhenyu | Chief Scientific Officer | Sale | 4,000 | $7.88 | $32K | 552.9K | View | |
| 2026-09-11 | 2026-09-14 | Van Well Daan | Chief Legal Officer | Sale | 6,168 | $7.63 | $47K | 338.9K | View |
Informational purposes only, not investment advice.
tormere.com/research/SOPH · generated 2026-10-04
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-21 | Muken Ross | S | 422 | $3,515.26 |
| 2026-09-21 | CARDOZA GEORGE | S | 774 | $6,447.42 |
| 2026-09-14 | Menu Philippe | S | 5,000 | $39,416.5 |
| 2026-09-14 | Xu Zhenyu | S | 4,000 | $31,537.6 |
| 2026-09-11 | Van Well Daan | S | 6,168 | $47,088.98 |
Tormere — informational purposes only, not investment advice.